Table 3.
Menopausal symptom prevalence and severity across menopausal stages in women living with and without HIV in Harare
| Menopausal symptoms | HIV negative (n = 193) | HIV positive (n = 185) | Interaction p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre- (n = 94) |
Peri- (n = 28) |
Post- (n = 71) |
p value | Pre- (n = 79) |
Peri- (n = 23) |
Post- (n = 83) |
p value | ||
| Total | |||||||||
| MRS II total, mean (SD) | 4.4(4.6) | 6.1(5.0) | 5.6(4.9) | 0.095 | 7.4(6.3) | 11.4(7.8) | 6.1(5.7) | 0.004 | 0.014 |
| Any symptoms, n (%) | 70(74.7) | 25(89.3) | 53(74.6) | 0.233 | 70(88.6) | 23(95.8) | 66(79.5) | 0.029 | |
| Any moderate or severe symptoms, n (%) | 14(14.9) | 7(25.0) | 19(26.8) | 0.147 | 27(34.2) | 11(45.8) | 26(31.3) | 0.337 | |
| Somatic sub-domain | |||||||||
| Sub-domain total, mean (SD) | 2.1(2.2) | 3.3(2.4) | 3.2(2.9) | 0.012 | 2.9(2.8) | 4.8(2.8) | 2.8(2.5) | 0.010 | 0.033 |
| Any symptoms, n (%) | 36(38.3) | 16(57.1) | 39(54.9) | 0.055 | 37(46.8) | 18(78.3) | 42(50.6) | 0.027 | |
| Any moderate or severe symptoms, n (%) | 11(11.7) | 8(28.6) | 22(31.0) | 0.005 | 22(27.9) | 13(56.5) | 21(25.3) | 0.013 | |
| Psychological sub-domain | |||||||||
| Sub-domain total, mean (SD) | 1.3(2.0) | 1.5(1.8) | 1.1(1.6) | 0.824 | 2.8(2.9) | 3.8(3.6) | 1.5(2.0) | 0.001 | 0.013 |
| Any symptoms, n (%) | 28(29.8) | 11(39.3) | 19(26.7) | 0.471 | 45(57.0) | 16(69.6) | 31(37.4) | 0.006 | |
| Any moderate or severe symptoms, n (%) | 12(12.8) | 6(21.4) | 10(14.1) | 0.516 | 25(31.7) | 9(39.1) | 13(15.7) | 0.018 | |
| Urogenital sub-domain | |||||||||
| Sub-domain total, mean (SD) | 1.0(1.5) | 1.4(1.9) | 1.3(1.8) | 0.494 | 1.6(1.9) | 2.8(2.8) | 1.8(2.4) | 0.081 | 0.280 |
| Any symptoms, n (%) | 41(43.6) | 16(57.1) | 36(50.7) | 0.393 | 48(60.8) | 18(78.3) | 47(56.6) | 0.169 | |
| Any moderate or severe symptoms, n (%) | 25(26.6) | 9(32.1) | 23(32.4) | 0.684 | 35(44.3) | 16(69.6) | 35(42.2) | 0.058 | |
Comparison of menopausal symptoms by menopausal stage stratified by HIV status. MRS II: Menopause Rating Scale II; All continuous variables presented as mean (SD), Menopausal status (Pre-menopause, Peri-menopause, and Post-menopausal) All comparisons for categorical data presented were performed using the Chi-square test, Whilst means (SD) are presented for MRS II and sub-domain scores, Kruskal Wallis tests were used to compare medians across the menopausal stages given skewness of the data. Interaction test for the effect of menopause stage* HIV on menopausal symptoms